Carbylan Therapeutics Inc  

(Public, NASDAQ:CBYL)   Watch this stock  
Find more results for David McKune
0.540
-0.033 (-5.81%)
Real-time:   3:47PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.54 - 0.60
52 week 0.52 - 7.51
Open 0.60
Vol / Avg. 366,366.00/507,969.00
Mkt cap 14.27M
P/E     -
Div/yield     -
EPS -1.04
Shares 26.33M
Beta     -
Inst. own 81%

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -94385.71% -85675.86%
Operating margin -93257.14% -72537.93%
EBITD margin - -72079.31%
Return on average assets -49.78% -78.34%
Return on average equity -57.37% -968.84%
Employees 14 -
CDP Score - -

Address

3181 Porter Dr
PALO ALTO, CA 94304-1213
United States - Map
+1-650-8556777 (Phone)
+1-650-8559119 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Carbylan Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of combination therapies. It focuses on the development of Hydros-TA, its intra-articular (IA) injectable product candidate to treat pain associated with osteoarthritis (OA) of the knee. Hydros-TA delivers both rapid pain relief with a low dose corticosteroid triamcinolone acetonide (TA) and sustained pain relief from its hyaluronic acid viscosupplement. Its Hydros-TA is a combination IA product, designed to provide both rapid and sustained pain relief with a single six milliliters intra-articular injection consists of over 52 milligrams of bacterially derived HA and over 10 milligrams of TA. Its first Phase III clinical trial of Hydros-TA, COR1.1, was a multi-center, international, randomized, double-blind, three-arm trial. Its Phase IIb clinical trial of Hydros-TA, COR1.0, was a multicenter, randomized, double-blind feasibility study.

Officers and directors

David M. Renzi President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
John B. McKune Principal Accounting Officer, Corporate Controller
Age: 40
Bio & Compensation  - Reuters
Marcee M. Maroney Vice President - Clinical Affairs
Age: 46
Bio & Compensation  - Reuters
David Saul Director
Bio & Compensation  - Reuters
Steven L. Basta Independent Director
Age: 48
Bio & Compensation  - Reuters
Albert Cha M.D., Ph.D. Independent Director
Age: 43
Bio & Compensation  - Reuters
David M. Clapper Independent Director
Age: 64
Bio & Compensation  - Reuters
Keith A. Katkin Independent Director
Age: 43
Bio & Compensation  - Reuters